Conjugate Or Complex Includes Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Intercellular Mediator, Or Fragment Thereof Patents (Class 424/195.11)
-
Patent number: 7442376Abstract: Forms of differentially acting glycoprotein hormones are disclosed. These compositions are of the formula ?1-(linker1)m-?-(linker2)n-?2;??(1) ?1-(linker1)m-?2-(linker2)n-?;??(2) ?-(linker1)m-?1-(linker2)n-?2;??(3) ?2??-(linker)m-?1; or??(4) ?1-(linker)m-???2??(5) wherein each of ?1 and ?2 has the amino acid sequence of the ? subunit of a vertebrate glycoprotein hormone or a variant of said amino acid sequence, as variants are defined herein. “?” designates the ? subunit of a vertebrate glycoprotein hormone or a variant thereof, “linker” refers to a covalently linked moiety that spaces the ?1 and ?2 subunits at appropriate distances from the ? subunit and from each other. “?” is a noncovalent link. Each of m and n is independently 0 or 1.Type: GrantFiled: August 21, 2003Date of Patent: October 28, 2008Assignee: Washington UniversityInventors: Irving Boime, David Ben-Menahem
-
Patent number: 7430476Abstract: This invention relates to a novel approach for identification of T-cell epitopes, that give rise to an immune reaction in a living host. By means of this novel method biological compounds can be generated which have a no or at least a reduced immunogenicity when exposed to the immune system of a given species and compared with the relevant non-modified entity. Thus the invention relates also to novel biological molecules, especially proteins and antibodies, obtained by the method according to the invention.Type: GrantFiled: February 18, 2002Date of Patent: September 30, 2008Assignee: Merck Patent GmbHInventors: Francis J. Carr, Graham Carter, Tim Jones, Stephen Williams, Anita Hamilton
-
Patent number: 7427655Abstract: The present invention relates to synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid ? which can be used alone or conjugated to an immunostimulatory molecule in an immunizing composition for inducing an immune response to amyloid ? peptides and amyloid deposits.Type: GrantFiled: September 19, 2003Date of Patent: September 23, 2008Assignee: New York UniversityInventors: Blas Frangione, Thomas Wisniewski, Einar M. Sigurdsson
-
Publication number: 20080166369Abstract: A preparation combining a complex of a cancer antigen and a hydrophobized polysaccharide with an agent, e.g., an extract from hemolytic streptococcus, which binds to a Toll-like receptor to stimulate the antigen presenting cells activates all of the antigen presenting cells, the killer T cells and the helper T cells which are major immune cells when antigen specific immunity against cancer cells is induced and activated, and exerts a potent vaccinal effect. A vaccine preparation of the present invention induces immune responses to the cancer antigen, in particular, has effects of activation and induction of cytotoxic T cells and helper T cells, and thus, can be used as a therapeutic or preventive vaccine for cancer therapy.Type: ApplicationFiled: December 27, 2005Publication date: July 10, 2008Applicant: Immuno Frontier, Inc.Inventors: Hiroshi Shiku, Shin-ichi Kageyama
-
Patent number: 7378096Abstract: Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an infectious disease. Preferred immunogenic polypeptides include gp100, her2/neu ECD-PD, ICD and M. tuberculosis antigens. The pharmaceutical compositions of the invention can be used for the treatment or prevention of cancer or infectious disease.Type: GrantFiled: June 3, 2002Date of Patent: May 27, 2008Inventors: John R. Subjeck, Robert A. Henderson, Elizabeth A. Repasky, Latif Kazim, Xiang-Yang Wang, Masoud H. Manjili
-
Patent number: 7341730Abstract: This invention provides for polypeptides that have surprising anti-angiogenic activity. These peptides are derived from Saposin B, a previously known protein involved in the hydrolysis of sphingolipids. In addition, methods of treating mammals with these anti-angiogenic polypeptides are provided, as well as the pharmaceutical compositions used to treat. Furthermore, the polypeptides of this invention can be used in fusion proteins, wherein the fusion proteins also comprise cell targeting or cytotoxic moieties. Also provided is the receptor to which these polypeptides bind.Type: GrantFiled: July 12, 1999Date of Patent: March 11, 2008Assignee: University of Southern CaliforniaInventor: Parkash S. Gill
-
Patent number: 7320793Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.Type: GrantFiled: January 18, 2002Date of Patent: January 22, 2008Assignees: Cytos Biotechnology AG, Novartis Pharma AGInventors: Wolfgang A Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Luond, Matthias Staufenbiel, Peter Frey
-
Patent number: 7270822Abstract: The use of a biologically active complex of ?-lactalbumin, selected from HAMLET (human ?-lactalbumin made lethal to tumour cells) or a biologically active modification thereof, or a biologically active fragment of either of these, in the preparation of a medicament for use in the treatment of papilloma, such as cutaneous papillomas.Type: GrantFiled: May 8, 2003Date of Patent: September 18, 2007Assignee: NYA Hamlet Pharma ABInventor: Catharina Svanborg
-
Patent number: 7264810Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.Type: GrantFiled: January 18, 2002Date of Patent: September 4, 2007Assignee: Cytos Biotechnology AGInventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek
-
Patent number: 7208157Abstract: The present invention is based on the discovery of a composition that provides targeted ubiquitination. Specifically the composition contains a ubiquitin pathway protein binding moiety which recognizes a ubiquitin pathway protein and a targeting moiety which recognizes a target protein. In addition, the present invention provides libraries of compositions, where each composition contains a ubiquitin pathway protein binding moiety and a member of a molecular library. The libraries of the present invention can be used to identify proteins involved in a predetermined function of cells.Type: GrantFiled: November 18, 2002Date of Patent: April 24, 2007Assignees: California Institute of Technology, Yale University, The Regents of the University of CaliforniaInventors: Raymond J. Dashaies, Craig Crews, Kathleen M. Sakamoto
-
Patent number: 7201905Abstract: A novel fusion protein, comprising a receptor-antagonizing domain and a positive immunomodulator domain, characterized, for example, by its ability to block apoptosis and/or inhibit endocrine response, is useful in treating cancer. For example, a human prolactin antagonist-interleukin 2 (hPRLA-IL-2) fusion protein combines apoptosis induction and immuno-therapy to combat cancer in the breast or prostate.Type: GrantFiled: March 23, 2001Date of Patent: April 10, 2007Assignee: Greenville Hospital SystemInventors: Wen Y. Chen, Thomas E. Wagner
-
Patent number: 7163683Abstract: Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are disclosed. Accordingly, these conjugates are useful for treating antibody-mediated pathologies that are caused by foreign or self immunogens.Type: GrantFiled: July 16, 2004Date of Patent: January 16, 2007Assignee: La Jolla Pharmaceutical CompanyInventors: Paul A. Barstad, G. Michael Iverson
-
Patent number: 7128913Abstract: The present invention refers to conjugates of erythropoietin with poly(ethylene glycol) comprising an erythropoietin glycoprotein having an N-terminal ?-amino group and having the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have the sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or a rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to one poly(ethylene glycol) group of the formula —CO—(CH2)x—(OCH2CH2)m—OR wherein the —CO of the poly(ethylene glycol) group forms an amide bond with said N-terminal ?-amino group; and wherein R is lower alkyl; x is 2 or 3; and m is from about 450 to about 1350.Type: GrantFiled: December 11, 2001Date of Patent: October 31, 2006Assignee: Hoffmann-La Roche Inc.Inventors: Josef Burg, Alfred Engel, Reinhard Franze, Bernd Hilger, Hartmut Ernst Schurig, Wilhelm Tischer, Manfred Wozny
-
Patent number: 7128903Abstract: A pharmaceutical preparation useful for treating a skin or mucous membrane lesion is provided. The pharmaceutical preparation including, as active ingredients, a therapeutically effective amount of trichloroacetic acid and hydrochloric acid, or trichloroacetic acid and formic acid or all three of these acids and optionally a crosslinking/fixating/preserving agent. Additional preparations are also described.Type: GrantFiled: October 3, 2001Date of Patent: October 31, 2006Assignee: Innovative Pharmaceutical Concepts (IPC) Inc.Inventor: Pinchas Burstein
-
Patent number: 7128911Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular a RANKL protein, RANKL fragment or RANKL peptide-VLP-array. More specifically, the invention provides a composition comprising a virus-like particle and at least one RANKL protein, RANKL fragment or RANKL peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of bone diseases and as a pharmaccine to prevent or cure bone diseases and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: GrantFiled: November 7, 2002Date of Patent: October 31, 2006Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Patrik Maurer, Gunther Spohn
-
Patent number: 7115266Abstract: The present invention provides conjugates of peptide derivatives of the mammalian peptide hormones angiotensinogen, angiotensin I and angiotensin II, presented in a repetitive scaffold by coupling the peptide derivatives to a carrier, particularly a virus-like particle (VLP). The invention also provides methods of producing such conjugates, and immunotherapeutic uses of the resulting immunogen conjugates for the therapy and prophylaxis of conditions associated with the renin-activated angiotensin system.Type: GrantFiled: October 4, 2002Date of Patent: October 3, 2006Assignee: Cytos Biotechnology AGInventor: Martin Bachmann
-
Patent number: 7105162Abstract: Pharmaceutical composition containing at least one peptide or protein (fragment) with an immunomodulatory activity together with an adjuvant. The peptide is derived from a pathogenic agent or a tumour antigen. The adjuvant is capable of increasing the binding of the peptide to the cells of the individual to be treated or of increasing the entry of the peptide into the cells and strengthening the immunomodulatory activity of the peptide. Preferred adjuvants are basic polyamino acids such as polyarginine or polylysine, optionally conjugated with a cellular ligand such as a carbohydrate group or transferrin. The composition is particularly intended for use as a vaccine, e.g. as a tumour vaccine.Type: GrantFiled: February 21, 1997Date of Patent: September 12, 2006Assignee: Boehringer Ingelheim International GmbHInventors: Walter Schmidt, Max Birnstiel, Peter Steinlein, Michael Buschle, Tamàs Schweighoffer
-
Patent number: 7087232Abstract: The present invention relates to the establishment of a cultivation condition that is suitable for the large-scale production of pharmacologically active filtrates from a culture of A. camphorata, in particular, by optimizing the agitation rate and/or pH value during the cultivation. The present invention also relates to a process for obtaining pharmacologically active compositions from a culture of A. camphorata through a series of fractionation. This invention is further directed to the uses of the above compositions in the preparation of pharmaceutical compositions.Type: GrantFiled: October 30, 2003Date of Patent: August 8, 2006Assignee: Council of Agriculture, Executive YuanInventors: Mei-Chiao Wu, Ren-Chang Huang, Shie-Jea Lin, Bor-Cheh Wang
-
Patent number: 7056512Abstract: Disclosed are novel methods for increasing muscle mass by means of immunization against Growth Differentiation Factor 8 (GDF-8, myostatin). Immunization is preferably effected by administration of analogues of GDF-8 which are capable of inducing antibody production against homologous GDF-8. Especially preferred as an immunogen is homologous GDF-8 which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the tertiary structure of the homologous GDF-8. Also disclosed are nucleic acid vaccination against GDF-8 and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for identification of useful immunogenic GDF-8 analogues, methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.Type: GrantFiled: July 20, 2000Date of Patent: June 6, 2006Assignee: Pharmexa A/SInventors: Steen Klysner, Soren Mouritsen, Torben Halkier
-
Patent number: 7038016Abstract: The present invention employs a dissolved activated polyethylene glycol (aPEG) or related molecule that has been passed through a filtration means for the substantial reduction of bioburden or endotoxin levels in the aPEG solution. The resulting filtered aPEG solution can be used for the preparation of a PEGylated hemoglobin solution containing substantially reduced levels of bioburden or endotoxin.Type: GrantFiled: August 21, 2001Date of Patent: May 2, 2006Assignee: Apex Bioscience, Inc.Inventors: Todd Lewis Talarico, Cyrus John Stacey
-
Patent number: 7037501Abstract: A method to alter the phenotype of animals, e.g., avians, which employs passive and active immunization is provided.Type: GrantFiled: January 4, 2001Date of Patent: May 2, 2006Assignee: Regents of the University of MinnesotaInventors: Mohamed E. El Halawani, Seungkwon You
-
Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
Patent number: 7022521Abstract: The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.Type: GrantFiled: June 24, 2003Date of Patent: April 4, 2006Assignee: Emory UniversityInventor: Stephen R. Hanson -
Patent number: 7014856Abstract: This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.Type: GrantFiled: January 21, 1994Date of Patent: March 21, 2006Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Philip Ordway Livingston, Friedhelm Helling
-
Patent number: 7001601Abstract: This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.Type: GrantFiled: June 7, 1995Date of Patent: February 21, 2006Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Philip Ordway Livingston, Friedhelm Helling
-
Patent number: 6998125Abstract: The present invention provides a synergistic composition and methods for treating neoplastic or cancerous growths as well as for treating such patients in order to restore or boost hematopoiesis. The present invention comprises administration of the combination of a cytotoxic T-lymphocyte inducing composition and at least one agent which is capable of neutralizing or down regulating the activity of tumor secreted immunosuppressive factors, separately or in combination.Type: GrantFiled: May 14, 2001Date of Patent: February 14, 2006Assignee: Biogen IDEC Inc.Inventors: Nabil Hanna, Gary R. Braslawsky, Kandasamy Hariharan
-
Patent number: 6984384Abstract: Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an infectious disease. The pharmaceutical compositions of the invention can be administered to a subject, thereby providing methods for inhibiting M. tuberculosis-infection, for inhibiting tumor growth, for inhibiting the development of a cancer, and for the treatment or prevention of infectious disease. The invention further provides a method for producing T cells directed against a tumor cell or a M. tuberculosis-infected cell, wherein a T cell is contacted with an APC that is modified to present an hsp110 or grp170 polypeptide and an immunogenic polypeptide associated with a tumor or with the M. tuberculosis-infected cell.Type: GrantFiled: September 29, 2000Date of Patent: January 10, 2006Assignee: Health Research, Inc.Inventors: John R. Subjeck, Robert A. Henderson, Elizabeth A. Repasky, Latif Kazim, Xiang-Yang Wang
-
Patent number: 6967022Abstract: This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.Type: GrantFiled: June 7, 1995Date of Patent: November 22, 2005Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Philip Ordway Livingston, Friedhelm Helling
-
Patent number: 6962694Abstract: A method for inactivating target cells in the presence of T cells by bringing the two types of cells in contact with a superantigen (SAG) in the presence of an immune modulator, characterized in that at least one of the superantigen and the immune modulator is in the form of a conjugate between a “free” superantigen (Sag) and a moiety targeting the conjugate to the target cells. A superantigen conjugate complying with the formula (1) (T)x(Sag)y(IM)z; a) T is a targeting moiety, Sag corresponds to a free superantigen, IM is an immune modulator that is not a superantigen and T, Sag and IM are linked together via organic linkers B; b) x, y and z are integers that typically are selected among 0-10 and represent the number of moieties T, Sag and IM, respectively, in a given conjugate molecule, with the provision that y>0 and also one or both of x and z>0. The superantigen conjugate is preferably a triple fusion protein.Type: GrantFiled: July 21, 1998Date of Patent: November 8, 2005Assignee: Active Biotech AGInventors: Morten Soegaard, Lars Abrahmsen, Peter Lando, Goran Forsberg, Terje Kalland, Mikael Dohlsten
-
Patent number: 6942663Abstract: Methods for treating maladies such as cutaneous vascular lesions. A patient in need of vascular lesion treatment is identified. A hyperosmotic agent is administered to a region adjacent the lesion. Blood flow velocity is slowed within the region using the hyperosmotic agent, and the lesion is exposed to laser radiation.Type: GrantFiled: March 10, 2003Date of Patent: September 13, 2005Assignee: Board of Regents, The University of Texas SystemInventors: Gracie Vargas, Jennifer K. Barton, Eric K. Chan, Thomas E. Milner, Ashley J. Welch
-
Patent number: 6936253Abstract: This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.Type: GrantFiled: June 7, 1995Date of Patent: August 30, 2005Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Philip Ordway Livingston, Friedhelm Helling
-
Patent number: 6929797Abstract: The present invention is directed to a conjugate which includes at least one vitamin D moiety thereof and at least one targeting molecule moiety to pharmaceutical compositions of the conjugate, and to methods for using the conjugate for target-specific delivery of vitamin D or analogs thereof to tissues in need thereof. When a particularly preferred form is administered to a patient, the targeting molecule component of the conjugate of this invention seeks out and binds to a tissue of interest, such as bone or tumor tissue, where the vitamin D has a therapeutic effect.Type: GrantFiled: February 13, 1998Date of Patent: August 16, 2005Assignee: Bone Care International, Inc.Inventors: Richard B. Mazess, Charles W. Bishop
-
Patent number: 6923966Abstract: Methods for treating treatment-naive as well as treatment-experienced patients having melanoma to increase the progression-free survival time involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., preferably pegylated interferon alpha-2b, as adjuvant therapy to definitive surgery are disclosed.Type: GrantFiled: July 12, 2001Date of Patent: August 2, 2005Assignee: Schering CorporationInventors: Mary Ellen Rybak, Esther Helen Rose
-
Patent number: 6916476Abstract: This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.Type: GrantFiled: June 7, 1995Date of Patent: July 12, 2005Assignee: Sloan-Kettering Institute for Cancer InstituteInventors: Philip Ordway Livingston, Friedhelm Helling
-
Patent number: 6888016Abstract: Our invention concerns a mixture of CLA glycerides, and/or CLA-fatty acids and or CLA-alkyl esters and another component, wherein the other component (=component A) is selected for its capacity to alleviate problems related to insulin resistance in mammals, using CLA rich diets and/or foods and/or food supplements using an appropriate in vitro test so that in at least one step of the in vitro test, as described in the text, an improvement in test results is obtained of at least 4% by the blend of the CLA derivative and component A when compared to the CLA derivative only. The inventon further concerns CLA rich dietic food, food supplements and foods containing the combination of CLA and component A as defined, while also the use of this combination for achieving an alleviation of insulin resistance is part of the invention.Type: GrantFiled: October 1, 2002Date of Patent: May 3, 2005Assignee: Loders Croklaan USA LLCInventors: Anna Louise Brown, Frederick William Cain, Ingrid Celestina Mohede, Preyesh Parmar, Julia Sarah Rogers, Ulrike Schmid
-
Patent number: 6887474Abstract: The present invention relates generally to methods and compositions for targeting, delivering, and activating platelet-dependent vascular occlusion agents. In particular, antibodies carrying platelet binding agents are targeted to hyperplastic cells or tissues, such as the vasculature of solid tumor masses; the platelet binding agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the formation of a platelet-mediated thrombus-causing vessel occlusion.Type: GrantFiled: November 12, 1999Date of Patent: May 3, 2005Assignee: ViRexx Medical CorporationInventors: Michael William Stewart, Roland Henryk Person, Antoine Noujaim
-
Patent number: 6866848Abstract: An antigenic polypeptide of factor VIII comprises a polypeptide included between the Glutamic Acid 1649 and Asparagine 2019, preferably between Arginine 1652 and Arginine 1917 of the polypeptide of factor VIII, or a polypeptide included between Alanine 108 and Methionine 355, or a polypeptide included between Aspartic Acid 403 and Aspartic Acid 725, or a polypeptide included between Lysine 2085 and Lysine 2249.Type: GrantFiled: July 14, 1995Date of Patent: March 15, 2005Assignee: Croix-Rouge de BelgiqueInventors: Ruth Laub, Mario Di Giambattista
-
Patent number: 6858211Abstract: This invention relates to conjugates of the O-specific polysaccharide of E. coli O157 with a carrier, and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly it relates to the use of polysaccharides containing the tetrasaccharide repeat unit: (?3)-?-D-GalpNAc-(1?2)-?-D-PerpNAc-(1?3)-?-L-Fucp-(1?4)-?-D-Glcp-(1?), and conjugates thereof, to induce serum antibodies having bactericidal (killing) activity against hemolytic-uremic syndrome (HUS) causing E. coli, in particular E. coli O157. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against against E. coli, in particular E. coli O157, and are useful to prevent and/or treat illnesses caused by E. coli O157.Type: GrantFiled: July 20, 1998Date of Patent: February 22, 2005Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Shousun Chen Szu, John B. Robbins, Yvonne Ageyman Konadu, Edward Konadu
-
Patent number: 6841160Abstract: This invention pertains to vaccine compositions comprising a mixture of antigen, such as pneumococcal or meningococcal antigen, and interleukin IL-12, which may be adsorbed onto a mineral in suspension. The pneumococcal or meningococcal antigen may be conjugated to a carrier molecule. These vaccine compositions modulate the protective immune response to the antigen.Type: GrantFiled: November 4, 2003Date of Patent: January 11, 2005Assignee: Wyeth Holdings CorporationInventors: Vincent J. LaPosta, John H. Eldridge
-
Patent number: 6831059Abstract: The present invention relates to an agent comprising a neurotoxin, methods for making the agents and methods for treating endocrine disorders, for example gonadotrophin related illnesses. Preferably, the agent comprises at least a portion of a botulinum toxin.Type: GrantFiled: March 15, 2001Date of Patent: December 14, 2004Assignee: Allergan, Inc.Inventor: Stephen Donovan
-
Patent number: 6827937Abstract: This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core antigen particles comprising immunogens, epitopes, or other related structures, crosslinked thereto by ligands which are HBV capsid-binding peptides that selectively bind to HBV core protein. Such particles may be used as delivery systems for a diverse range of immunogenic epitopes, including the HBV capsid-binding peptides, which advantageously also inhibit and interfere with HBV viral assembly by blocking the interaction between HBV core protein and HBV surface proteins. Mixtures of different immunogens and/or capsid-binding peptide ligands may be crosslinked to the same HBV core particle. Such resulting multicomponent or multivalent HBV core particles may be advantageously used in therapeutic and prophylactic vaccines and compositions, as well as in diagnostic compositions and methods using them.Type: GrantFiled: May 29, 2003Date of Patent: December 7, 2004Assignee: Biogen Idec MA Inc.Inventor: Kenneth Murray
-
Patent number: 6821517Abstract: Molecular adjuvants are disclosed comprising an antigen presenting cell-targeting ligand functionally linked to an immunogen, e.g. tumor associated antigens, bacterial or viral antigens, etc. Methods are disclosed for delivery of these molecular adjuvants to patients, resulting in the transduction of activating signals to the targeted antigen presenting cell, thereby enhancing the immune response to the co-delivered immunogen.Type: GrantFiled: April 17, 1998Date of Patent: November 23, 2004Assignee: The Board of Regents of the University of NebraskaInventors: Sam D. Sanderson, Michael A. Hollingsworth, Richard A. Tempero
-
Patent number: 6805865Abstract: Compositions and methods effective for eliciting an immune response for inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise a naturally occurring or synthetic protein, peptide, or protein fragment containing all or an active portion of a growth factor in a pharmaceutically acceptable carrier. The preferred growth factors comprise basic fibroblast growth factor and vascular endothelial growth factor. The methods involve administering to a human or animal the compositions described herein in a dosage sufficient to elicit an- immune response. The methods are useful for treating diseases and processes mediated by undesired and uncontrolled cell proliferation, such as cancer, particularly where uncontrolled cell proliferation is influenced by the presence of growth factors.Type: GrantFiled: March 11, 1999Date of Patent: October 19, 2004Assignee: EntreMed, Inc.Inventors: John W. Holaday, Antonio Ruiz, John Madsen, Stacy M. Plum
-
Patent number: 6797806Abstract: A polypeptide comprising a portion of the sequence of the general formula (I): CNPGSGGRKVFELVGEPSIYCTSNDDQVGIWSG, of 6-23 amino acids in length and comprising sequence a) and/or b): a) GGRKVF, b) FELVGEPSIY multimeric and chimeric derivatives, pharmaceutiocal compositions containing them and their use in therapy.Type: GrantFiled: December 1, 1998Date of Patent: September 28, 2004Assignee: AdProTech LimitedInventors: Danuta Ewa Irena Mossakowska, Colin Michael Edge, Richard Anthony Godwin Smith
-
Patent number: 6797275Abstract: This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, S. typhi bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies againt S. typhi and are useful to prevent and/or treat illnesses caused by S. typhi.Type: GrantFiled: September 1, 2000Date of Patent: September 28, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Zuzana Kossaczka, Shousun Chen Szu, John B. Robbins
-
Patent number: 6797272Abstract: New immunological carrier systems, DNA encoding the same, and the use of these systems, are disclosed. The carrier systems include chimeric proteins which comprise a leukotoxin polypeptide fused to a selected antigen. The leukotoxin functions to increase the immunogenicity of the antigen fused thereto.Type: GrantFiled: November 24, 1997Date of Patent: September 28, 2004Assignee: University of SaskatchewanInventors: Andrew A. Potter, Mark J. Redmond, Huw P. A. Hughes
-
Patent number: 6773707Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a heat shock protein complexed to a hybrid antigen comprising an antigenic domain and a heat shock protein-binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.Type: GrantFiled: August 10, 2000Date of Patent: August 10, 2004Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: James E. Rothman, Franz-Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takechi, Mark Mayhew
-
Patent number: 6761892Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a heat shock protein complexed to a hybrid antigen comprising an antigenic domain and a heat shock protein-binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.Type: GrantFiled: April 20, 2000Date of Patent: July 13, 2004Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: James E. Rothman, Franz-Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takechi, Mark Mayhew
-
Publication number: 20040133099Abstract: Diagnosing or treating a human ear includes transporting a conjugated nanoparticle or a magnetically responsive nanoparticle into a human's middle or inner ear. Otologic nanophoresis includes electrically, magnetically or electromagnetically driving a nanoparticle through a membrane of the ear, including a tympanic membrane, a round window membrane, an oval window membrane, or a circulatory membrane. An otologic diagnostic device includes a nanoparticle conjugated with a material selected from the group consisting of lipids, proteins, growth factors, growth hormones, antioxidants, free radical scavengers, steroid preparations, and metabolically active substances; an otologic therapeutic device includes the same categories of substances and chemotherapeutic drugs. Another otologic composition includes a nanoparticle conjugated with a substance perceptible to magnetic resonance imaging.Type: ApplicationFiled: December 17, 2003Publication date: July 8, 2004Inventors: R. Kent Dyer, Jack V.D. Hough
-
Patent number: 6737064Abstract: A novel permeability enhancing peptide (PEP) is a fragment of interleukin-2. When joined to a delivery vehicle that can target a tumor site, the PEP can increase the subsequent uptake of antineoplastic or tumor imaging agents. The PEP can be chemically joined to a monoclonal antibody to form an immunoconjugate. Alternatively, an expression vector is genetically engineered to express a fusion protein. The fusion protein has an antigen-binding portion joined to the PEP. The PEP is most effective when it takes the form of a dimer, linked by a disulfide bridge. The PEP is substantially free of cytokine activity and produces minimal toxic side effects on normal tissues.Type: GrantFiled: May 9, 2002Date of Patent: May 18, 2004Assignee: The University of Southern CaliforniaInventors: Alan L. Epstein, Leslie A. Khawli
-
Patent number: 6730302Abstract: The present invention provides a carrier for the delivery of molecules with biological function into both cellular and nuclear compartments. The carrier disclosed is heat shock protein 70 (“Hsp70”), or a fragment of Hsp70 as described herein, as a vehicle for directed, noninvasive delivery of molecules, such as proteins, peptides, or DNA, that may modulate cellular activity. The present invention also encompasses the use of Hsp70, or a fragment thereof, to modulate cellular activity, preferably to modulate nuclear activity in a cell or cells.Type: GrantFiled: November 16, 1999Date of Patent: May 4, 2004Assignee: Bristol-Myers Squibb CompanyInventors: Sheri M. Fujihara, Steven G. Nadler